Johnson & Johnson to Buy Abiomed for $16.6 Billion
- November 04, 2022
Johnson & Johnson (J&J) has entered into a definitive agreement to acquire cardiovascular technologies firm Abiomed in a deal valued at roughly $16.6 billion, the company announced November 1.
ARTICLE TAGS
You must be logged in to access this content.